Nöreleptik malign sendrom: Bromokriptin ile tedavi edilen bir olgu
Nöroleptik malign sendrom (NMS), özellikle antipsikotik tedavi esnasında nadir olarak görülen ve potansiyel olarak ölümcül olan bir sendromdur. Bu yazıda, hastanede uzun süredir tedavi altında bulunan, uzun yıllardır antipsikotik kullanımı ve birçok kez yatışları olan, şizoaffektif bozukluk tanısıyla izlenen bir olguda, oral ve depo antipsikotik kullanırken, oral antipsikotik ilaç tedavisinde yapılan doz artırımının ardından gelişen NMS ve ona yönelik tedavi yaklaşımı sunularak NMS tedavisinde bromokriptinin kullanımı tartışılmıştır.
Neuroleptic malignant syndrome: A case treated with bromocriptine
Neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome which is rarely seen during treatment with antipsychotic medications. In this paper, the treatment of NMS that developed after a dose increase in oral antipsychotic drug therapy with depot antipsychotics in a patient with schizoaffective disorder, who has used antipsychotic medications for a long time and was hospitalized many times was reported and the treatment approach and bromocriptine use in NMS was discussed.
___
- 1. Bottoni TN. Neuroleptic malignant syndrome: A brief review. Hosp Physician 2002; 38:58-63.
- 2. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: Case reports and a review of literature. Psychosomatics 2009; 50:8-15.
- 3. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876.
- 4. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: A review. Psychiatr Serv 1998; 49:1163–1172.
- 5. Rosebush P, Stewart T, Mazurek MF. Treatment of neuroleptic malignant syndrome: Are dantrolene and bromocriptine useful adjuntcs to supportive care? Br J Psychiatry 1991; 159:709-712.
- 6. Öncü F, Hariri A, Ceylan ME. Nöroleptik malign sendrom. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi 1998; 11:30-35.
- 7. Alpay N, Canbek Ö, Karamustafalıoğlu N, Karaakın Y. Serum fosfokinaz düzeyi (CPK) normal olan bir nöroleptik malign sendrom (NMS) vakası. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi 1998; 11:38-40.
- 8. Bajjoka I, Patel T, O’Sullivan T. Risperidone-induced neuroleptic malignant syndrome. Ann Emerg Med 1997; 30:688-700.
- 9. Dave M. Two Cases of Risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995; 52:1233-1234.
- 10. Sullivan CF. A possible variant of neuroleptic malignant syndrome. Br J Psychiatry 1987; 151:689-690.
- 11. Goldwasser HD, Hooper JF, Spears NM. Concomittant treatment of neuroleptic malignant syndrome and psychosis. Br J Psychiatry 1989; 154:102-104.
- 12. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9792 Chinese inpatients exposed to neuroleptics: A prospective study. Am J Psychiatry 1990; 147:1149-1155.
- 13. Zubenko G, Pope HG Jr. Management of a case of neuroleptic malignant syndrome with bromocriptine. Am J Psychiatry 1983; 140:1619-1620.
- 14. Azorin JM, Bouchacourt M, Lavergne T, Giudicelli S. Syndrome malin des neuroleptiques. Efficacité de la bromocriptine. Presse Med 1984; 13:1702.
- 15. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome. Succesful treatment with bromocriptine. JAMA 1983; 249:386-388.
- 16. Tomruk NB, Poyraz BÇ, Kılıç A, Karşıdağ Ç, Alpay N. Uzun süreli kombine antipsikotik tedavi sırasında nöroleptik malign sendrom: Olgu sunumu. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi 2010;23:142-144.
- 17. Tural Ü, Önder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010; 64:79–87.
- 18. Arkonaç O, Verimli A, Soysal H, Atalay H, Türkcan A. EKT ile tedavi edilen iki nöroleptik malign sendrom olgusu. Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi 1991; 4:61-63.
- 19. Reulbach U, Dütsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, Bleich S. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11:R4 (doi:10.1186/cc5148).